GlassScriptPhysician profile
Erin A Barnes
NPI 1235689472
$902.29
in general payments reported to CMS, 2019-2025
14 companies · $97.09 in 2025
The $97.09 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $85.75 · 2023: $196 · 2024: $348 · 2025: $97.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $144.47 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $142.27 | 2021-2024 | Airsupra |
| Axsome Therapeutics, INC. | $124.80 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $116.74 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $102.45 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.33 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.02 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $35.40 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.20 | 2022 | |
| Merck Sharp & Dohme LLC | $22.91 | 2024 | Zerbaxa, Dificid |
| Boston Scientific Corporation | $16.67 | 2024 | Watchman Access System |
| Abbvie INC. | $15.14 | 2021 | |
| Pfizer INC. | $11.26 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.63 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.